WHY DID PEPTIDE SCIENCES SHUT DOWN OVERNIGHT?

WHY DID PEPTIDE SCIENCES SHUT DOWN OVERNIGHT?

The inside story: FDA enforcement, pharmaceutical litigation, and the quality failures behind a $7.4M/month closure

At 2:00 PM Eastern on March 6, 2026, a business generating $7.4 million per month posted three sentences on its homepage and went dark. There was no warning, no refund plan, and no explanation. Peptide
Sciences — the largest gray-market research peptide vendor in the United States — was gone. The company closed voluntarily: not raided, not shut by court order. That quiet, deliberate exit tells you most of what you need to know about what was coming next.

EDUCATIONAL DISCLAIMER

FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY

This white paper discusses regulatory enforcement actions and market events for educational purposes only. Nothing here constitutes legal or medical advice. The regulatory landscape is changing rapidly, and conditions described reflect March 2026. Consult a healthcare provider and attorney for guidance specific to your situation. LiveWell Peptides does not sell gray-market research peptides.

WHO WAS PEPTIDE SCIENCES — AND WHY DID IT MATTER?

Peptide Sciences was not a garage operation. It was the dominant force in the US gray-market research peptide space — a decade-old company based in Henderson, Nevada, offering hundreds of compounds under “for research use only” labeling.

At its peak it drew over one million website visitors per month, with December 2025 sales reported at $7.4 million in a single month. The catalog covered everything researchers wanted: BPC-157,
TB-500, semaglutide, tirzepatide, retatrutide, growth hormone secretagogues, anti-aging peptides, and more — all marketed at 99%+ purity, with claims of WHO/GMP and ISO-certified manufacturing partners.

When a company this size disappears with three sentences and no warning, the explanation is not bad luck. It is a calculated exit from a landscape that had become impossible to survive.

THE THREE-SENTENCE GOODBYE

“VOLUNTARY” WAS A CAREFUL CHOICE OF WORDS

The Peptide Sciences announcement described the closure as “voluntary.” Healthcare law firm Frier Levitt has offered a plain-language translation of what that likely means: the company’s legal team advised that the risk of
forced closure — complete with raids, seized assets, and criminal exposure — outweighed any benefit of continuing to operate. “Voluntary” is what you call it when the alternative is worse.

THREE FORCES THAT COLLAPSED THE GRAY-MARKET MODEL

The shutdown was not triggered by one dramatic moment. It was the endpoint of three separate pressures that built simultaneously over 24 months and made the gray-market model mathematically unsustainable.

FORCE ONE — THE FDA WENT FROM LETTERS TO BOOTS ON THE GROUND

For years, “research use only” functioned like a magic shield. Vendors applied the label to vials of human-consumable compounds and the FDA mostly sent letters. That era ended in June 2025 when federal agents physically walked into Amino Asylum’s warehouse and the site went dark the same afternoon.

The shift was ideological, not just tactical. By 2025, the FDA’s position had hardened: a molecule with physiological effects on humans is a drug. A label does not change what a molecule does.
Frier Levitt healthcare attorneys were telling their clients that the RUO disclaimer provided “essentially zero legal protection.” The warning letters that had been routine since 2023 now came with DOJ and FBI coordination.

THE SCIENCE SAYS

THE “RESEARCH USE ONLY” DEFENSE WAS ALWAYS A LEGAL FICTION

The FDA has been consistent since 1938: if a compound has pharmacological activity in humans, it requires approval as a drug — regardless of the label. The research peptide industry built
a billion-dollar market on the hope that the FDA would not enforce this position aggressively. By 2025 that hope was exhausted.
FORCE TWO — ELI LILLY AND NOVO NORDISK DECLARED LEGAL WAR
The pharmaceutical companies that invented the GLP-1 revolution were watching gray-market vendors sell imitations of their most profitable products. Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) were being sold online for a fraction of pharmacy prices. The response was fast, overwhelming, and federal.

In March 2024, Eli Lilly filed a complaint with the US International Trade Commission against 12 vendors. By January 2025 the ITC issued a General Exclusion Order — blocking all trademark-infringing tirzepatide imports from entering the country. Any vendor selling tirzepatide after that date was not in a regulatory gray zone. They were violating a federal order.

Novo Nordisk ran a parallel campaign against compounded semaglutide. When the FDA declared the semaglutide shortage resolved in February 2025, the legal exemption that had allowed hundreds of pharmacies to produce GLP-1 analogs legally simply ceased to exist.

DID YOU KNOW?

THE GLP-1 GRAY MARKET WAS WORTH $328 MILLION — THEN IT WAS CUT OFF

US peptide imports from China reached $328 million in the first 9 months of 2025 — nearly double the prior year. Much of that was gray-market GLP-1 compounds. When the ITC exclusion order, FDA
shortage resolution, and DOJ prosecution campaign converged, that revenue stream did not slow down. It was severed.

FORCE THREE — THE QUALITY DATA WENT PUBLIC AND IT WAS DAMAGING

The third force was internal, and perhaps the most damaging. Independent testing platform Finnrick Analytics had been systematically testing Peptide Sciences products and publishing
the results publicly. The data was not just imperfect. For some flagship products it was disqualifying.

Retatrutide was Peptide Sciences’ most hyped product — the cutting-edge triple agonist that biohackers were paying premium prices to obtain. Every single one of 37 tested samples failed. A
counterfeit was flagged in November 2025. The company never publicly responded to the results.

A vendor can survive FDA warning letters. It can survive legal pressure from pharmaceutical companies. Surviving all three simultaneously — while independent labs are publicly documenting that your flagship product is potentially counterfeit — is a different calculation entirely.

THE 24-MONTH ENFORCEMENT TIMELINE

The overnight shutdown was the final scene of a two-year story. Here is how it unfolded, event by event:

THE CRUEL IRONY

THE REVERSAL CAME ONE WEEK TOO LATE

On February 27, 2026 — exactly one week before Peptide Sciences closed — HHS Secretary RFK Jr. announced on the Joe Rogan Experience that approximately 14 of 19 restricted Category 2 peptides would return to Category 1, restoring legal access through licensed compounding pharmacies. He called the original FDA ban “illegal” and said it “created the gray market.” But as legal experts immediately noted: a podcast announcement is not a regulatory update. No formal rule had changed. The market damage was already done.

WHAT ABOUT SCIENCE.BIO?

Science.bio told a quieter but parallel story. Founded in 2019 as the successor to IRC.Bio (which the FDA had pressured to close over SARMs in 2018), Science.bio built a loyal following through genuine quality commitment — independent third-party testing, transparent COA documentation, and a catalog that included SARMs, nootropics, and research peptides.

By most accounts, Science.bio did things better than most gray-market vendors. Their testing was more transparent. Their documentation was more rigorous. And in January 2026, they still closed. Their
farewell email said: “Getting more difficult and more expensive.”

Unlike Peptide Sciences, Science.bio refunded or fulfilled all outstanding orders before closing — a meaningful distinction. The conclusion was the same either way: the regulatory and legal
environment had made the business model unviable, even when you played by the rules.

THE LESSON FROM SCIENCE.BIO

DOING THINGS RIGHT WAS NOT ENOUGH TO SURVIVE

Science.bio had arguably the best quality documentation in the gray-market peptide space. Third-party testing. Batch-specific COAs. Transparent sourcing. They closed anyway. The issue was
not primarily quality — it was the legal framework itself. “Research use only” stopped being a viable business category, and that affected the bad actors and the good ones equally.

THE SAFETY REALITY THE INDUSTRY DID NOT WANT TO TALK ABOUT

The regulatory crackdown was not purely about intellectual property or market control. There was a genuine safety problem, and the data behind it was stark.

In 2025, two women were hospitalized and placed on ventilators after receiving peptide injections at a longevity conference in Las Vegas. A ProPublica investigation covered the incident. These
were not fringe cases — they were the visible edge of a much larger problem.

The TikTok videos of biohackers reconstituting unverified vials on kitchen counters without gloves were not edge cases either. Online peptide advertising surged 678% from 2022 to 2024. Chinese
imports nearly doubled to $328 million in 2025. More volume through less regulated channels produced exactly the outcomes that regulators had warned about.

WHAT THIS MEANS IF YOU HAVE PRODUCTS FROM THESE VENDORS

QUALITY VARIED DRAMATICALLY — AND RECONSTITUTED PEPTIDES DEGRADE FAST

Finnrick’s testing showed wide inconsistency across the Peptide Sciences catalog. BPC-157 scored an A (7.8/10). Retatrutide scored a failing E across 37 samples. If you have reconstituted
vials, they degrade within 30 days even when refrigerated, while lyophilized powder stored at proper temperatures retains potency longer. If you have pending orders or store credit from Peptide
Sciences, contact your credit card company promptly — chargebacks are typically available within 60-120 days of the transaction.

WHAT HAPPENS NEXT — THE MARKET IS SPLITTING

The compounds are not disappearing. The market is restructuring — from an unregulated gray zone into two distinct, very different channels.

The RFK Category 1 reclassification — when formally published — will restore legal access to approximately 14 peptides including BPC-157, TB-500, epithalon, selank, semax, and others through
licensed compounding pharmacies. This is not a return to the gray market. It requires a physician’s prescription and a licensed compounder. The days of buying injectable peptides online
without medical oversight are over.

PRACTICAL GUIDE — WHAT TO DO RIGHT NOW

IF YOU HAD PENDING ORDERS WITH PEPTIDE SCIENCES:

• File a credit card chargeback immediately — use reason code “merchant ceased operations”
• Document everything: order confirmations, account balances, payment receipts
• Most cards allow chargebacks 60-120 days from transaction date — do not wait
• If the chargeback fails, file a consumer protection complaint with your state attorney general

IF YOU WERE RELYING ON GRAY-MARKET COMPOUNDS FOR ONGOING RESEARCH:

• Monitor FDA.gov and HHS.gov for formal publication of the Category 1 reclassification
• Once official, licensed compounding pharmacies with a physician’s prescription are the path
• Verify any new vendor with independent third-party COAs from accredited labs — not in-house testing
• Require HPLC purity, mass spectrometry identity, AND endotoxin testing documentation
• Avoid any vendor still selling tirzepatide imports — the ITC exclusion order remains in full effect

The bottom line: The compounds that researchers depend on are not gone — they are moving into a more regulated channel. That transition is disruptive, and it requires a physician relationship and a prescription. It also provides something the gray market never could: verified quality, legal protection, and medical oversight. For the peptide research community, this is not the end of the story. It is the end of the beginning.

WHERE LIVEWELL FITS INTO THIS PICTURE

LiveWell Peptides operates as a research-chemical supplier, not a compounding pharmacy — our products are sold strictly for laboratory and in-vitro research, not for human or animal use. The events described above are a useful reference point for anyone evaluating a research-peptide supplier, regardless of which one they choose.

• Documentation you can check before you buy. Every LiveWell batch ships with a Certificate of Analysis confirming identity and purity — published on our COA page rather than supplied only on request.
• Independent, not in-house, testing. Each lot is verified by HPLC for purity and mass spectrometry for identity, with third-party laboratories involved alongside in-house quality control.
• A documented US manufacturing location. LiveWell’s cGMP facility is based in Dallas, Texas — a fact that is checkable, not a claim taken on faith.

None of this is a guarantee against the kind of regulatory shift described above; the compliance landscape for this category continues to move. But the Finnrick data on Peptide Sciences makes a specific point worth sitting with: even a large, established vendor can carry batch-to-batch quality that varies dramatically by product. Published, batch-specific documentation is what lets a researcher verify that for themselves, rather than relying on brand reputation alone.

THE BIGGER PICTURE

THE ERA OF “RESEARCH USE ONLY” IS OVER. WHAT REPLACES IT MATTERS MORE.

Peptide Sciences built something remarkable — a massive, trusted marketplace for compounds that millions of people genuinely wanted access to. The regulatory framework that destroyed it was
blunt, imperfect, and sometimes contradictory. The safety failures it exposed were also real. The path forward is more friction, more oversight, and more legitimacy — which ultimately serves the
researchers and patients who depend on these compounds most.

FREQUENTLY ASKED QUESTIONS

Why did Peptide Sciences shut down?

Peptide Sciences closed voluntarily in March 2026 after facing FDA enforcement actions, pharmaceutical industry litigation over trademark-infringing GLP-1 imports, and independent lab testing that revealed quality failures in some of its flagship products — including a 37-sample failure rate for its Retatrutide line.

Is it still legal to buy research peptides online?

The “research use only” label no longer offers meaningful legal protection for vendors selling peptides intended for human use. Some compounds are shifting toward a prescription-and-compounding-pharmacy model rather than direct online sales. Genuine research-use compounds sold to laboratories for in-vitro study remain a distinct category from consumer-facing gray-market sales.

What should I do if I had a pending order with Peptide Sciences?

File a credit card chargeback as soon as possible, citing that the merchant ceased operations. Keep records of your order confirmation and payment receipts. If the chargeback is denied, contact your state attorney general’s consumer protection office.

Did other peptide vendors close for the same reasons?

Yes. Amino Asylum was raided by federal agents in June 2025, Paradigm Peptides’ founders pleaded guilty to charges involving contaminated products in December 2025, and Science.bio closed voluntarily in January 2026 citing rising compliance costs — despite having comparatively strong testing and documentation practices.

Does a Certificate of Analysis guarantee a peptide is safe?

A Certificate of Analysis documents identity and purity for a specific batch, tested by a named laboratory — a verifiable record rather than a marketing claim. It does not itself constitute a safety or efficacy claim for any use, and products sold strictly for laboratory research are not evaluated by the FDA for human use.

SOURCES & REFERENCES

News & Industry Coverage

1. PeptideProtocolWiki. Peptide Sciences Shut Down: What Happened and What It Means for the Industry. March 2026.
2. PeptidesExplorer. Peptide Sciences Shut Down: What Happened (March 2026). March 2026.
3. Peptide Examiner. Why Did Peptide Sciences Close Down? March 2026.
4. Peplogix. What Happened to Peptide Sciences? Inside the Shutdown. March 2026.
5. Muscle and Brawn. Peptide Sciences Shut Down: What Happened and Where to Buy Now. March 2026.
6. All About Peptides. Peptide Sciences Pulls the Plug: Major Research Supplier Shuts Down. March 2026.
7. Rapamycin.news. Science.bio Closes. January 2026.

Data, Regulatory & Legal Sources

8. Finnrick Analytics. Independent testing of Peptide Sciences products — 123 samples, 10 peptides. Dec 2024–Mar 2026.
9. Grips Intelligence. Peptide Sciences e-commerce analytics ($7.4M December 2025 sales). March 2026.
10. U.S. International Trade Commission. General Exclusion Order — Certain Tirzepatide Products. January 2025.
11. FDA. Warning Letters to Research Peptide Vendors. December 2024.
12. FDA. GLP-1 Drug Shortage Resolution Announcement. February 2025.
13. FDA. Enforcement Action — Amino Asylum Warehouse. June 2025.
14. FDA. Warning Letters to GLP-1 Compounders (50+ letters). September 2025.
15. DOJ. Paradigm Peptides — Guilty Pleas Entered. December 2025.
16. Kennedy RFK Jr. Category 1 Peptide Reclassification Announcement. Joe Rogan Experience. February 27, 2026.
17. Frier Levitt Healthcare Law. Research Use Only Disclaimer Analysis. 2025.
18. LegitScript. Online Peptide Advertising Growth: 678% from 2022 to 2024. 2024.
19. U.S. Customs. Chinese Peptide/Hormone Compound Imports: $328 million, Q1-Q3 2025. 2025.
20. Huang T, et al. Quality Assessment of Internet-Purchased Research Peptides. Drug Test Anal. 2024.
21. FDA. Bulk Drug Substances Category 2 List. Updated 2024.

FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY • This publication is for educational purposes only and does not constitute legal or medical advice. The regulatory landscape described reflects conditions as of March 2026 and is subject to rapid change. LiveWell Peptides does not sell gray-market research peptides. All compounds mentioned are discussed for educational purposes only. Consult a licensed healthcare provider and attorney for any decisions related to peptide access or regulatory compliance.

It’s Not Just Peptide Sciences: The 2025–2026 Vendor Shutdown Wave

Peptide Sciences was the biggest name to go dark — but far from the only one. Since mid-2025, at least nine major research peptide and research chemical vendors have shut down, been raided, or gone offline, including Science.bio, Amino Asylum, Paradigm Peptides, Royal Research, and All American Peptide. The pattern points to industry-wide pressure, not isolated business failures.

Why did Science.bio close?

Science.bio announced its permanent closure on January 27, 2026, stating the decision came “after careful consideration.” Unlike some other vendors, the closure was voluntary — there was no reported raid or enforcement action against the company — and Science.bio committed to fulfilling or refunding all outstanding orders. Notably, this was the company’s second exit: it had previously shut down in 2022 before relaunching. Its farewell notice now warns that any site claiming to be Science.bio or its successor is fraudulent.

What happened to All American Peptide?

All American Peptide’s situation was different. According to public court records, the company’s owners pleaded guilty to federal conspiracy charges involving the distribution of unapproved drugs, with forfeitures reported at over $3 million. A “down for maintenance” page is rarely just maintenance in this market — researchers searching for the site should treat it as permanently offline.

Why are so many vendors closing at once?

Public reporting points to several converging forces: FDA enforcement escalated from warning letters (over 50 sent to peptide vendors by late 2025) to warehouse raids and criminal prosecutions; pharmaceutical companies including Eli Lilly and Novo Nordisk filed lawsuits against GLP-1 suppliers; independent testing exposed quality failures at several major vendors; and payment processors began exiting the category. In February 2026, HHS also announced that 14 restricted peptides would return to legal compounding channels — a signal that regulators intend to replace the unregulated market, not tolerate it.

How to Vet a Research Peptide Supplier That Will Still Be Here Next Year

The shutdown wave rewrote the rules for supplier selection. Before ordering from any vendor, qualified researchers should verify:

• Published, batch-specific COAs — not “available on request,” but posted publicly and matched to the lot you receive
• Independent third-party testing — HPLC purity plus mass spectrometry identity verification, from a named lab
• Transparent US manufacturing — a verifiable facility and cGMP processes, not a reshipping operation
• Strict research-use-only compliance — vendors that publish dosing guidance or wellness claims are exactly the ones regulators target first
• Responsive support and clear policies — companies that vanish overnight rarely had either

Where Researchers Are Sourcing Now

LiveWell Peptides manufactures research peptides in our own cGMP facility in Dallas, Texas — every batch is third-party verified to ≥99% HPLC purity, with batch-specific Certificates of Analysis published openly. US orders placed before 2pm CT (Mon–Fri) ship same-day with cold-chain packaging. Browse the full research catalog, or schedule a call for bulk and documentation inquiries. All products are strictly for laboratory research use only — not for human or animal consumption.